AHFS® DI® contains the most trustworthy drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses. Benefits that are unique to only AHFS® DI® include:
The only print compendium designated by the U.S. Congress
The only compendium published by a professional and scientific society
The only reference that has been trusted by pharmacists and other healthcare professionals for over 60 years
Learn more about related resources, electronic only monographs, and AHFS Clinical Drug Information here.
AHFS® Drug Information® 2020 Edition is not available as an eBook. The front matter is available for all to see below. ASHP has an online application called AHFS® Clinical Drug Information™ available for purchase. For more information, please visit the product site or contact Customer Relations here.
With extensive updated information on everything from management of opiate use disorder to orphan drugs, AHFS® Drug Information® 2020 Edition is a necessary addition to your pharmacy’s resources.
With expanded and revised content supported by more than 94,000 references and incorporating the advice of numerous subject matter experts, AHFS® DI™ helps you protect your patients and your practice. It’s the only print compendium designated by the U.S. Congress, the only compendium published by a professional and scientific society, and is the reference that has been trusted by pharmacists and other healthcare professionals for over 60 years.
AHFS® DI™ contains the most trustworthy drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.
Updates for this edition include:
Management of opiate use disorder
Multimodal pain management strategies, including expansion of information related to non-opiate analgesic agents and opiate-sparing drugs; management of pain and sedation in critically ill patients, including current best practices such as the concept of analgosedation and comparisons of various sedative agents used for ICU sedation
Newly published information on breakthrough oncology drugs approved as part of the FDA’s accelerated approval program
Updating of pharmacogenomic considerations related to dosage adjustments (e.g., tamoxifen) or risk of sensitivity reactions (e.g., allopurinol, phenytoin or fosphenytoin)
Updated information on non-oncology off-label uses (e.g., mycophenolate in treating scleroderma; ketamine use in treatment-resistant depression)
Your Comprehensive, Interactive Treatment and Drug Therapy Solution
A pharmacy professional’s indispensable digital tool, AHFS® Clinical Drug Information™ lets you rapidly toggle between a quick summary of the essentials and a comprehensive monograph view. Mark your favorites for easy access and take notes throughout.
By linking directly and in context to 20 additional specialty databases, it expands your access to real-time drug and safety updates, including quick access to current drug shortages information. Learn more here.
Published by Authority of the Board of the AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS®
American Hospital Formulary Service®
Elaine K. Snow, BS Pharm, Editor-in-Chief
Jane Miller, PharmD, Senior Associate Editor
Linda Kester, MS, Associate Editor
Natalie A. Mendham, PharmD, Associate Editor
Olin H. Welsh, Jr., PharmD, Associate Editor
Joan D. Heydorn, BS, Assistant Editor
Shingyee Cindy Huang, PharmD, Assistant Editor
Lily L. Leu, PharmD, BCOP, Oncology Specialist Assistant Editor
Lisa M. Kohoutek, PharmD, BCPS, Assistant Editor for Injectables
Laura R. Kennedy, PharmD, BCPS, Senior Drug Information Analyst
Natalie C. Rosanelli, PharmD, Senior Drug Information Analyst
Kaitlin M. Harves, PharmD, BCPS, Drug Information Analyst